

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SUNSHINE LAKE PHARMA CO., LTD.

廣東東陽光藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6887)

**INSIDE INFORMATION
COMPLETION OF THE H SHARE FULL CIRCULATION**

This announcement is made by Sunshine Lake Pharma Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 29 August 2025, 29 April 2026 and 6 May 2026 (the “**Announcements**”) in relation to the H Share Full Circulation. Unless the context requires otherwise, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

The Company is pleased to announce that the conversion of the 208,390,308 Domestic Shares into H Shares was completed on 21 May 2026, and the listing of such Converted H Shares on the Stock Exchange will commence at 9:00 a.m. on 22 May 2026.

SHAREHOLDING STRUCTURE

The shareholding structure of the Company (taking into account of the treasury shares) before and upon the completion of the Conversion and Listing is set out as follows:

Type of shares	Before the completion of the Conversion and Listing		Upon the completion of the Conversion and Listing	
	Number of shares	Approximate percentage of total issued shares of the Company (%)	Number of Shares	Approximate percentage of total issued shares of the Company (%)
Domestic Shares	463,943,215	80.45	255,552,907	44.32
H Shares	<u>112,712,832</u>	<u>19.55</u>	<u>321,103,140</u>	<u>55.68</u>
Total	<u>576,656,047</u>	<u>100.00</u>	<u>576,656,047</u>	<u>100.00</u>

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sunshine Lake Pharma Co., Ltd.
Dr. ZHANG Yingjun
Chairman

Dongguan, the PRC
21 May 2026

As at the date of this announcement, the executive directors are Dr. ZHANG Yingjun and Dr. LI Wenjia, the non-executive directors are Mr. ZHANG Yushuai, Mr. TANG Xinfu, Mr. ZHU Yingwei, Mr. ZENG Xuebo, Ms. DONG Xiaowei and Ms. WANG Lei, and the independent non-executive directors are Dr. LI Xintian, Dr. MA Dawei, Dr. YIN Hang Hubert, Dr. LIN Aimei and Dr. YE Tao.